These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20412613)

  • 1. Timeliness of MMR vaccination and barriers to vaccination in preschool children.
    Jeong YW; Park BH; Kim KH; Han YR; Go UY; Choi WS; Kong KA; Park H
    Epidemiol Infect; 2011 Feb; 139(2):247-56. PubMed ID: 20412613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timeliness of MMR vaccination--influence on vaccination coverage.
    Dannetun E; Tegnell A; Hermansson G; Törner A; Giesecke J
    Vaccine; 2004 Oct; 22(31-32):4228-32. PubMed ID: 15474712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of measles, mumps and rubella vaccine coverage in 3 year old children in twelve French counties. Time-trends and related factors].
    Rotily M; Guagliardo V; Fontaine D; Garros B; Mayer C; Arrighi J; Woronoff AS; Ledesert B; Lepec R; Chabaud F; Janvrin MP; Baudier F
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):331-41. PubMed ID: 11567200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The two-dose measles, mumps, and rubella (MMR) immunisation schedule: factors affecting maternal intention to vaccinate.
    Pareek M; Pattison HM
    Br J Gen Pract; 2000 Dec; 50(461):969-71. PubMed ID: 11224968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy.
    Marin M; Nguyen HQ; Langidrik JR; Edwards R; Briand K; Papania MJ; Seward JF; LeBaron CW
    Clin Infect Dis; 2006 Feb; 42(3):315-9. PubMed ID: 16392073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study.
    Mrozek-Budzyn D; Kiełtyka A; Majewska R
    Pediatr Infect Dis J; 2010 May; 29(5):397-400. PubMed ID: 19952979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
    Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
    Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: development and validation of an evidence-based measurement instrument.
    Brown KF; Shanley R; Cowley NA; van Wijgerden J; Toff P; Falconer M; Ramsay M; Hudson MJ; Green J; Vincent CA; Kroll JS; Fraser G; Sevdalis N
    Vaccine; 2011 Feb; 29(8):1700-9. PubMed ID: 21185850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccinations in early infancy -- results of an epidemiological cross-sectional study in Hamburg].
    Fell G; David C; Reintjes R
    Gesundheitswesen; 2005 Jan; 67(1):27-32. PubMed ID: 15672303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
    Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
    Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.